Trial Profile

INHALE-1st: Technosphere Insulin (Afrezza®) In Combination With Basal Insulin For Youth With Newly-Diagnosed Type 1 Diabetes

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin (Primary) ; Insulin (Primary)
Indications Hyperglycaemia; Type 1 diabetes mellitus
Focus Therapeutic Use
Acronyms INHALE-1st
Sponsors MannKind Corporation

Most Recent Events

09 Feb 2026 According to MannKind Corporation media release, first patient has been enrolled in this study, at the Barbara Davis Center for Diabetes in Aurora, Colorado, one of about 10 clinical sites participating.
05 Feb 2026 Planned End Date changed from 1 Jun 2027 to 1 Jul 2027.
05 Feb 2026 Planned primary completion date changed from 1 Oct 2026 to 1 Nov 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com